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Summary
AIMS OF THE STUDY: Noninvasive ventilation (NIV) is a
well-established treatment option for hypercapnic respira-
tory failure; however, the best mode of ventilation remains
unknown. The aim of this retrospective study was to com-
pare patients’ adherence to NIV using either pressure sup-
port ventilation (PSV) or intelligent volume-assured pres-
sure support (iVAPS).
PATIENTS AND METHODS: In this retrospective cohort
study, we assessed in- and outpatients suffering from hy-
percapnic respiratory failure of various aetiologies (chronic
obstructive pulmonary disease [COPD], obese COPD
[body mass index >30 kg/m2], obesity hypoventilation syn-
drome and other diseases such as amyotrophic lateral
sclerosis or interstitial lung disease) after NIV initiation
with PSV or iVAPS. Adherence to treatment was com-
pared between these modes using the Wilcoxon test.
Within-group differences were tested using linear regres-
sion models. Mortality and emergency hospital readmis-
sion rates were modelled using Kaplan-Meier estimates
and Cox proportional hazards models.
RESULTS: Adherence to treatment was similar in both
groups throughout the observation period – after 6 weeks:
PSV 363 min/night (interquartile range [IQR] 200–448),
iVAPS 369 min/night (IQR 310–468) (p = 0.619); after
1 year: PSV 423 (323–500), iVAPS 429 (298–475) (p =
0.901); at the last follow up: PSV 481 (395–586), iVAPS
426 (391–565) (p = 0.284). NIV reduced PaCO2 signif-
icantly compared with baseline at all follow-ups: PSV
−1.29/−1.49/−1.49 kPa, iVAPS −1.47/−1.23/−1.24 kPa, p
<0.001 each, PSV vs iVAPS: p = 0.250, 0.756 and 0.352,
respectively. Median survival time (PSV 5.06 years, iVAPS
median not reached; p = 0.800) and time to first readmis-
sion (PSV 3.6 years, iVAPS 7.33 years, p = 0.200) did not
differ between groups. Obese COPD patients had a longer
time to hospital readmission than lean COPD patients (3.8
vs 1.5 years, hazard ratio (HR) 0.39, 95% confidence in-
terval [CI] 0.16–0. 74; p = 0.007). Good adherence (>4 h/
night and >80% nightly usage) was associated with a low-
er mortality rate (HR 0.34, 95% CI 0.15–0.77; p = 0.010).
CONCLUSION: In a real-world setting of a mixed pop-
ulation with hypercapnic respiratory failure, iVAPS and
PSV seem to be similarly effective in improving gas ex-
change and demonstrate excellent adherence to treat-
ment. A longer survival was noted in NIV-adherent pa-
tients. Randomised controlled studies are necessary to
identify patients who might benefit more from hybrid venti-
lation modes.
Introduction
Noninvasive ventilation (NIV) is a well-established treat-
ment for acute and chronic respiratory failure caused by
various underlying pathophysiologies [1–4]. Volume- or
pressure-pre-set ventilation modes (PSV) are commonly
used, but technical developments in ventilators have pro-
vided new hybrid modes that combine both features of
ventilation and focus on a target volume (e.g., average
volume assured pressure support [AVAPS], Philips, Mur-
rysville, USA; intelligent volume assured pressure support
[iVAPS], ResMed, Bella Vista, Australia) [5]. These hy-
brid modes are based on algorithms that enable the venti-
lator to adapt the pressure support and, to a lesser degree,
also back-up rates to the patient’s requirements [6]. In the-
ory, these modes should thereby be able to maintain normal
ventilation even if respiratory conditions change (e.g., po-
sitional changes during sleep, rapid eye movement sleep).
Studies comparing volume-assured modes of NIV with
PSV revealed that volume-assured modes can be at least
as effective as conventional PSV in reducing CO2 in dif-
ferent diseases [7–12]. Recent NIV studies showed similar
frequencies of sleep disturbances with ventilators using
volume-assured modes or PSV [11, 13–18]. Adherence to
iVAPS over 1 month was better in one prospective study
[18].
To the best of our knowledge only one recent study report-
ed long-term treatment data (>3 months) for hybrid modes
[19], but this did not focus on comparison between PSV
and iVAPS. Several long-term studies in patients using dif-
ferent NIV modes showed a reduction in PaCO2 and good
compliance (>4 h/night) [18–24]. Longer usage during the
night-time (>4 h/night) was associated with a greater re-
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duction of PaCO2 [25]. A relevant reduction of PaCO2
was associated with a survival benefit in non-obese and
obese patients with chronic obstructive pulmonary disease
(COPD) [22, 26].
The aim of this study was to compare adherence to NIV of
patients suffering from hypercapnic respiratory failure of
different aetiologies using either pressure support ventila-
tion (PSV) or intelligent volume-assured pressure support
(iVAPS) in a real-world setting.
Material and methods
Study setting and participants
In a retrospective single centre study, we searched the in-
stitutional database (Kantonsspital St. Gallen, Department
of Pulmonary and Sleep Medicine, Switzerland) for pa-
tients who were started on mechanical home ventilation
for the first time or were restarted after a period without
NIV between 1 January 1 2012 and 30 October 2015. Fol-
low-up ended on 31 August 2019. The inclusion criteria
were age >18 years, ventilation with PSV or iVAPS, at
least one inpatient or outpatient follow-up visit in the ven-
tilator clinic and the usage of a Stellar™ 100 or Stellar™
150 ventilator (ResMed, Bella Vista, Australia), a VPAP
ST™ (ResMed, Bella Vista, Australia), or a S9VPAP ST™
(ResMed, Bella Vista, Australia). Only Stellar™ 150 and
S9VPAP ST™ provided the iVAPS mode at that time. Pa-
tients were included regardless of sex, underlying disease,
or whether NIV was started in acute or chronic respiratory
failure. Patients who discontinued the treatment were in-
cluded in the analysis until the point when no further data
were available. Exclusion criterion was a refusal of a gen-
eral informed consent allowing anonymised collection of
the patient’s data.
Included patients were categorised into those using PSV or
iVAPS mode and subclassified into disease-specific groups
as follows: (1) lean COPD with body mass index (BMI)
<30 kg/m2 (forced expiratory volume in 1 second / forced
vital capacity [FEV1/FVC] <0.7, current or ex-smoker)
and daytime hypercapnia (PaCO2 >6 kPa) and/or ≥2 COPD
exacerbations/year, (2) obese COPD with BMI >30 kg/
m2 (FEV1/FVC <0.7, current or ex-smoker) and daytime
hypercapnia, (3) obesity hypoventilation syndrome (OHS)
(BMI >30 kg/m2 and daytime hypercapnia) either with or
without obstructive sleep apnoea (OSA) with an apnoea-
hypopnoea index (AHI) ≥5/h, or (4) other disease (amy-
otrophic lateral sclerosis, interstitial lung disease, di-
aphragm paralysis) [27].
Outcomes
The primary outcome was adherence to NIV, which was a
composite of average usage per night in hours and % of
nights with usage between follow-up visits. The follow-
up appointments were ordered by the treating physician
with the first usually being within 6 weeks (±3 weeks)
after starting NIV and thereafter at least annually (52 ± 12
weeks).
Good adherence was arbitrarily defined as usage on >80%
of nights and >4 h/night. Secondary outcomes were ven-
tilation parameters measured by the ventilator, emergency
hospital admissions due to cardiac and pulmonary illness,
all-cause mortality and reduction of PaCO2.
Data collection
We collected demographics, anthropometric data, pul-
monary function test results, arterial blood gas results, the
number of hospitalisations due to cardiac and pulmonary
illnesses, death (institutional system with reporting to the
hospital if patients on NIV die who are not treated anymore
in our institution) and continued use of NIV from the med-
ical records up to 31 August 2019. Data on the ventilator
usage and detailed ventilation parameters (usage in days,
mean usage in min/night, expiratory positive airway pres-
sure (EPAP), inspiratory positive airway pressure (IPAP),
tidal volume, AHI and unintentional leak [calculated by
the software as total leak minus intentional leak from the
utilised mask CO2 washout]) were collected from the rou-
tine downloads (ResScan™ software, ResMed, Bella Vista,
Australia).
Ventilator and ventilator settings
NIV was initiated according to clinical routine by a dedi-
cated NIV team [28]. Detailed information on settings and
set-up of NIV can be found in the appendix.
Statistics
This is an exploratory analysis. Data were reported de-
scriptively as percentage or median and interquartile range
(IQR). Between-group differences for proportions were
tested using the Wilcoxon test or using two-sided chi-
square tests or Fisher’s exact tests. For within-group dif-
ferences, a two-sided paired t-test was used. Time to event
data (time to emergency hospital readmission, death) were
analysed using Kaplan-Meier estimates and Cox propor-
tional hazards models in order to adjust for confounding
effects and other variables. Patients who were lost to fol-
low-up were included until the last follow-up. PSV was
considered as reference for the survival analysis. The sig-
nificance level was set to 0.05 for all analyses. All analyses
were done using the R statistical software, version 3.5 [29].
Ethics
This study was approved by the local ethics committee
(EKOS 2017-00278). Written informed patient consent




We included 98 patients. Fifty-four patients were started
on home NIV for hypercapnic respiratory failure in PSV
mode, 44 on iVAPS. Baseline data are shown in table 1.
There were no statistically significant differences between
the two treatment groups in the parameters. Patient flow is
depicted in figure 1.
Adherence to NIV
At the first follow-up (median 42 days, IQR 32–59), ven-
tilator data were available for 86 patients (PSV n = 46,
iVAPS n = 40). After 1 year (358 days, 306–417) 63 data
sets were available (PSV n = 35, iVAPS n = 28) and 46
(PSV n = 30, iVAPS n = 16) were available for the last fol-
low-up (1584 days, 1182–1933). The composite endpoint
did not differ significantly between both modes at any fol-
low-up visit. The overall usage per night and the number
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of nights with usage were good and did not significantly
differ between the modes at any follow-up visit (table 2).
In the disease-specific subgroups, there were no differ-
ences for the composite endpoint (table S1 in the appen-
dix). A higher usage per night was noted in the group of
patients with other diseases using PSV as compared with
iVAPS (96%, 90–100%, n = 4 vs 69%, 9–86%, n = 6; p
= 0.042) after 1 year and in the obese COPD group at the
last follow-up (PSV 99% 95–100%, n = 12 vs iVAPS 96%,
82–98%, n = 8; p = 0.049) (table S1). At the last follow-up,
the subgroup analysis was limited to other disease, obese
COPD and OHS/OSA because of small sample sizes (table
S1).
Twenty-seven patients (15 female, 12 male) stopped the
treatment mode initially chosen: seven in the PSV group
(change to iVAPS n = 3 or continuous positive airway pres-
sure [CPAP] n = 1, after bariatric surgery n = 1, did not tol-
erate PSV n = 1, PaCO2 normalisation n = 1) after a median
of 790 days (IQR 200–950) and 20 patients in the iVAPS
group (change to PSV n = 2, average volume assured pres-
sure support [AVAPS] n = 1 or CPAP n = 1, insufficient
usage n = 2, intolerance n = 7, extensive weight loss n =
Table 1: Patients’ baseline characteristics.
Patient group according to mode of ventilation PSV iVAPS
Female/male (n) 16/38 21/23
Age 64 (58–69) (n = 54) 69 (61–73) (n = 44)
BMI (kg/m2) 31.4 (25.3–39.1) (n = 51) 37.0 (26.1–43.0) (n = 36)
Lean COPD (BMI <30 kg/m2) (n) 14 8
Obese COPD (BMI >30 kg/m2) (n) 18 16
OHS/OSA (n) 11 11
Other (n) 11 9
FEV1 (l) 1.09 (0.60–1.62) (n = 39) 1.33 (0.96–1.64) (n = 33)
FEV1 (%) 39 (24–59) (n = 37) 53 (39–61) (n = 31)
FVC (l) 2.18 (1.56–2.73) (n = 39) 2.09 (1.71–2.58) (n = 33)
FVC (%) 58 (46–74) (n = 37) 66 (54–74) (n = 32)
pH 7.41 (7.37–7.43) (n = 50) 7.40 (7.34–7.43) (n = 42)
PaO2 (kPa) 8.1 (6.5–9.3) (n = 50) 7.5 (6.7–8.9) (n = 43)
PaCO2 (kPa) 7.0 (6.3–7.8) (n = 50) 6.6 (5.8–8.0) (n = 43)
HCO3− (mmol/l) 30.6 (28.2–33.5) (n = 50) 29.5 (27.9–32.0) (n = 38)
Oxygen supplementation (l/min) 1 (0–2) (n = 48) 1 (0–2) (n = 42)
BMI = body mass index; COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; iVAPS = intelligent volume
assured pressure support; OHS = obesity hypoventilation syndrome; OSA = obstructive sleep apnoea; PSV = pressure support ventilation; Data are presented as numbers or
median followed by interquartile range (1st and 3rd) in parentheses.
Figure 1: Patient flow chart. ABGA = arterial blood gas analysis; AVAPS = average volume assured pressure support; CPAP = continuous
positive airway pressure; F/U = follow-up; iVAPS = intelligent volume assured pressure support; NIV = noninvasive ventilation; PSV = pressure
support ventilation;
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4, palliative setting n = 1, improvement of the lung dis-
ease n = 1, unclear n = 1) after 466 (240–1166) days. At
baseline there were no differences between these subjects
and those who continued the allocated treatment through-
out the study, regarding age (68 years, 58–74 vs 65 years,
60–71; p = 0.882), BMI (36.8 kg/m2, 25.8–41.2 vs 32.3
kg/m2, 24.3–40.1, p = 0.445), FEV1 (1.04 l, 0.64–1.64 vs
1.30 l, 0.69–1.63; p = 0.787), FVC (2.09 l, 1.58–2.46 vs
2.10 l, 1.67–2.73; p = 0.952), PaO2 (7.1 kPa, 6.4–9.6 vs 7.9
kPa, 6.8–9.0; p = 0.510), PaCO2 (7.0 kPa, 6.1–7.7 vs 6.7
kPa, 6.1–8.0; p = 0.921) or oxygen supplementation (2 l,
0.0–2.0 vs 0, 0–2; p = 0.174).
Four patients restarted NIV. Six patients were lost to fol-
low-up, two in the iVAPS and four in the PSV group.
Data from the ventilator
The AHI measured by the built-in ventilator software was
below 5 events/h in both groups and no statistically signif-
icant differences were found throughout the follow-up pe-
riod.
After 1 year, tidal volume was lower with PSV (430 ml,
380–540, n = 28 vs iVAPS 555 ml, 458–625, n = 28; p
= 0.008). Unintentional air leak was low overall and even
lower with PSV at the last follow-up (0 l/min, 0–3, n = 23
vs 7 l/min, 2–16, n = 15; p = 0.006). For further details see
table 2.
In the subgroup analysis, IPAP was lower in the OHS/OSA
patients treated with PSV (19 hPa, 17–20, n = 10 vs iVAPS
23 hPa, 20–28, n = 8; p = 0.044) at the first follow-up.
The AHI was lower in obese COPD patients using PSV (3,
0–5, n = 16 vs iVAPS 8, 2–9, n = 9; p = 0.029) after one
year. Tidal volume was lower in the obese COPD group
and OHS/OSA patients using PSV after 1 year (PSV 505
ml, 400–605, n = 16 vs iVAPS 595 ml, 570–670, n = 10; p
= 0.037, and 395 ml, 310–495, n = 8 vs 515 ml, 458–685,
n = 9, respectively; p = 0.040). Unintentional air leak was
lower in the obese COPD group using PSV at the last fol-
low-up (PSV 0 l/min, 0–6, n = 8 vs iVAPS 11 l/min, 4–45,
n = 8; p = 0.035). The other parameters were similar for
both modes in the disease-specific subgroups. Further de-
tails are shown in table S1.
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BMI = body mass index; EPAP = expiratory positive airway pressure; FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; IPAP = inspiratory positive
airway pressure; iVAPS = intelligent volume assured pressure support; PSV = pressure support ventilation Good usage was defined as use >80% of nights, >4 h/night. Data are
presented as median followed by interquartile range (1st and 3rd) in parentheses. * p <0.01 between groups; † p <0.0001 within group
Original article Swiss Med Wkly. 2021;151:w20506
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”. No commercial reuse without permission - https://smw.ch/permissions
Page 4 of 10
Blood gas analyses
Blood gas analyses revealed a marked reduction in PaCO2
by more than 1 kPa accompanied by an improvement of
HCO3− at all checks, irrespective of ventilation mode
(table 2, p >0.05 between groups; p-values between groups
for PaCO2 in chronological order: 0.251, 0.592, 0.352; for
HCO3− 0.512, 0.419, 0.903) or subgroup (table S1).
Hospitalisations and mortality
During the observation period 40 patients died, 14 who
were initially allocated to iVAPS and 26 initially allocated
to PSV. There were no differences in survival between
groups (HR 0.91, 95% confidence interval [CI] 0.47–1.76;
p = 0.80) (fig. 2A). Median survival time in the PSV group
was 5.06 years, a median survival time for the iVAPS mode
could not be calculated since <50% died. Median time to
hospital readmission was 3.6 years in the PSV group and
7.3 years in the iVAPS group (HR 0.63, 95% CI 0.33–1.21;
p = 0.164) (fig. 2B). Median time to any event (emergency
hospital readmission or death) was 3.4 years in the PSV
group. The median could not be calculated in the iVAPS
group (HR 0.58, 95% CI 0.31–1.1; p = 0.092) (fig. 2C),
since not enough events had occurred at the end of follow-
up.
If subjects were not adherent to NIV (PSV or iVAPS), the
median time to death was 2.68 years. A median was not
reached in the adherent group (HR 0.34, 0.15–0.77; p =
0.010) (fig. 3A). Median time to emergency hospital read-
mission was 4.8 years in the adherent group and 4.7 years
in the non-adherent group (HR 0.54, 0.24–1.22; p = 0.200)
(fig. 3B). For any event there was a risk reduction in the
adherent group (HR 0.44, 0.21–0.92; p = 0.040) (fig. 3C).
A subgroup analysis of obese and lean COPD patients re-
vealed no impact of BMI on the median time to death
(obese COPD 6.1 years vs lean COPD 3.9 years; HR 0.45,
0.20–1.15; p = 0.100). Median time to emergency hospital
readmission was significantly longer in obese COPD pa-
tients (3.8 years) than in lean COPD patients (1.5 years)
HR 0.39, (0.16–0.74; p = 0.007). A risk reduction was
also seen in median time to any event in obese compared
with lean COPD patients (3.8 years vs 1.5 years, HR 0.38,
0.18–0.77; p = 0.010).
Discussion
To the best of our knowledge, this is the largest study com-
paring patients using an iVAPS mode to a PSV mode with
an observational period longer than 3 months. In this ret-
rospective analysis, NIV was effective in improving alve-
olar ventilation within the first 6 weeks, which was main-
tained throughout the study period. The adherence to NIV
with the iVAPS mode was similar to PSV mode and good
in both groups. Furthermore, there were no differences in
mortality or time to the first emergency hospital readmis-
sion after the initiation of NIV.
The overall usage of NIV on a nightly basis was similar
irrespective of the ventilation mode. The length of NIV
per night (6–8 hours) was comparable to other NIV studies
with and without hybrid modes, including the largest avail-
able study done in long–term NIV [9, 11, 15, 19, 30, 31].
The similar length of nightly usage with both ventilation
modes differs from the result of a short-term study in a
mixed population with chronic respiratory failure, which
reported a longer duration of NIV usage per night with
iVAPS than with PSV [18]. In contrast, a recent Swiss
study found similar usage irrespective of ventilation mode,
comparable to our findings [19]. We speculate that the ear-
lier findings might be related to the study design, a longer
Figure 2: Kaplan-Meier curves for survival (A), emergency hospital readmission (B) and time to any event (death, readmission) (C) according
to ventilator mode. iVAPS = intelligent volume assured pressure support; PSV = pressure support ventilation
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observation period and thus potentially better habituation
to NIV, or differences in the cohorts [18].
Sleep quality has been addressed by several studies, all
without suggestion of a decreased sleep quality with
iVAPS [9, 14, 17, 18]. We did not perform sleep studies,
but the regular and long nightly usage of the ventilator in
our data supports the notion that sleep quality might have
been acceptable with both ventilation modes.
The improvement of arterial blood gases is in line with re-
cent studies [15, 19, 32]. Compared with other study pop-
ulations, we noticed an even more profound reduction of
PaCO2, especially in the OSA/OHS subgroup [2, 10, 31].
These differences could be related to a lower BMI in our
population, a longer observation period, newer ventilators,
different ventilator settings and a smaller sample size [2,
10, 31].
The mortality rate of about 15% after 1 year (median time
to death 5.06 years) with the PSV mode is comparable to
earlier studies of home mechanical ventilation [2, 33]. A
good adherence (>4 h/night and >80% nightly usage) re-
sulted in a lower mortality rate, which has been described
in obese COPD patients [26]. Obese COPD patients had a
longer time to emergency hospital readmission than lean
COPD patients. The hospital readmission rate after 1 year
of approximately 15% in our study was higher than in an
earlier Swiss study [2]. This might be explained by differ-
ences in the study populations, with a smaller proportion
of OHS/OSA patients in our cohort, as OHS/OSA patients
seem to have low rates of hospital admissions when using
NIV or CPAP [32].
The strengths of this study are the length of the observation
period, the usage of the ventilators from the same manu-
facturer, which limits algorithm bias, the marked reduction
of PaCO2 similar to published data from randomised con-
trolled trials, and the mixed cohort of patients, probably re-
sembling the patient populations of many NIV centres.
This study has certain limitations that have to be consid-
ered and that mainly come with the retrospective study de-
sign. Complete datasets were not available for all patients,
which may have biased our findings. Furthermore, this was
a single-centre study and the higher number of subjects
who stopped treatment because of intolerance in the iVAPS
group could have led to a selection bias. The small number
of patients in the subgroups somewhat limits the interpre-
tation of the subgroup data.
Conclusion
In a real-world setting of a mixed population with hyper-
capnic respiratory failure, iVAPS and PSV seem to be sim-
ilarly effective in improving gas exchange and demonstrate
excellent adherence to treatment. Longer survival was not-
ed in patients with good adherence to NIV. Randomised
controlled studies are necessary to identify patients who
might benefit more from hybrid ventilation modes.
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Figure 3: Kaplan-Meier curves for survival (A), emergency hospital readmission (B) and time to any event (death, readmission) (C) according
to usage of the ventilator.
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Appendix
Supplementary data
Ventilator and ventilator settings
NIV was initiated within clinical routine by a dedicated
NIV team (described in detail in [1]). The choice of the
ventilation mode was up to the treating physician’s discre-
tion. We usually treated the patient with NIV during the
day for a short period to acclimatise them to the interface
(orofacial or nasal mask) and the ventilator. Heating and
humidifying devices were used according to patient’s pref-
erences.
During the night, patients were observed using real-time
continuous PtCO2 measurements (SenTec AG, Therwil,
Switzerland) and a Tx Link box (ResMed, Bella Vista,
Australia) in order to receive real-time-volume curves
from the ventilator. The NIV team titrated the settings dur-
ing the night in the PSV group to achieve optimal oxygena-
tion (saturation of oxygen [SpO2] >92%), ventilation [Pt-
CO2 <6.7 kPa] and suppression of hypopnoea and apnoea
[oxygen desaturation index <15/h] and to encourage max-
imum patient cooperation [usage of the ventilator >4 h per
night].
We always used the spontaneous/timed mode (ST) with
backup rates set at 10–15/min, IPAP and EPAP were set in-
dividually to achieve optimal ventilation. Cycling and trig-
gering sensitivity were usually modulated to medium. In
the iVAPS group pressure support was initially set from
5–20 hPa, target alveolar ventilation was set according to
the manufacturer’s guidelines [2], and the backup rate was
set to 10–18/min; EPAP was set in the same manner as in
the PSV group.
The treating physicians adapted ventilator settings accord-
ing to symptoms, ventilator data, and blood gas analysis
during the follow-up period.
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Table S1: Subgroup ventilator data and blood gas values at follow-up 1, after 1 year and at the last follow-up.
Follow-up date Follow-up 1 42 days (32–59)
Disease COPD Obese COPD OSA/OHS Other

































Good usage (%) 46 (n = 13) 63 (n = 8) 80 (n = 15) 73 (n = 15) 89 (n = 9) 89 (n = 9) 67 (n = 9) 75 (n = 8)










































































































































































Follow-up date 1 year (0.84–1.14 yrs)
Disease COPD Obese COPD OSA/OHS Other

































Good usage (%) 50 (n = 6) 25 (n = 4) 53 (n = 15) 70 (n = 10) 75 (n = 8) 75 (n = 8) 100 (n = 5) 50 (n = 6)










































































































































































Follow-up date Last follow-up
4.3 yrs (3.2–5.3)
Disease COPD Obese COPD OSA/OHS Other
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Follow-up date Follow-up 1 42 days (32–59)
Disease COPD Obese COPD OSA/OHS Other
Mode of ventilation PSV iVAPS PSV iVAPS PSV iVAPS PSV iVAPS
















Good usage (%) 80 (n = 5) 100 (n = 1) 100 (n = 12) 75 (n = 8) 86 (n = 7) 100 (n = 3) 80 (n = 5) 50 (n = 4)














































































































































































EPAP = expiratory positive airway pressure; IPAP = inspiratory positive airway pressure; iVAPS = intelligent volume assured pressure support; PSV = pressure support ventilation
Good usage was defined as use >80% of nights, >4 h/night. Data are presented as median followed by interquartile range (1st and 3rd) in parentheses. Bold lettering p <0.05
between groups.
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